ERBB2 and gastric cancer: Current research focuses on overcoming these hurdles by exploring combination therapies, such as ICIs paired with chemotherapy or targeted agents, which have shown promising results, especially in human epidermal growth factor receptor 2 (HER2)-positive GC patients (2, 8).